MarketPeel
Insider Trading Intelligence
Pricing
…
TM

Tsveta Milanova

AGIO
CHIEF COMMERCIAL OFFICER · AGIOS PHARMACEUTICALS, INC. · CIK 0001957180
FILING MIX · LIFETIME47%/53%
BUYS
20
SELLS
23
TOTAL VALUE
$741.9K
COMPANIES
1
ACTIVE SINCE
Jan 2023
HOLDINGS NOW
3,000
AVG SELL PX
$29.29
TRADE KIND
SHOWING 43 / 43
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 13 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Tsveta Milanova, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+55.56%-0.57%+0.24%-0.81%-1.11%—
14d9+77.78%+0.19%+1.23%-1.04%-1.33%—
30d9+22.22%+9.53%+2.20%+7.33%+1.13%—
60d9+55.56%+6.45%+3.50%+5.82%+1.05%—
90d9+22.22%+9.30%+2.29%+9.47%+4.38%—
180d9(3 pending)+33.33%+33.88%+11.40%+22.48%+15.40%—
1y9(4 pending)+20.00%+28.56%+23.46%+5.10%+10.98%—
2y9(6 pending)+0.00%+22.92%+45.41%-22.49%-25.23%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AGIO · 3,000 shares · as of Jun 18, 2026
033,92167,841101,762135,682202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 20 buys / 23 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,000——3,000Jun 18, 2026Jun 23, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
3,000——9,000Jun 18, 2026Jun 23, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
8,500——50,091Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
8,500——8,500Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,262$34.71$113.2K46,829Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
4,000——8,000Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
5,666——40,459Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
5,666——5,667Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,187$28.96$34.4K41,591Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,681$28.96$48.7K38,778Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
4,000——42,778Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
52,000——52,000Mar 1, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,000——14,000Mar 1, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
8,475——0Jan 5, 2026Jan 7, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,872$27.02$77.6K34,793Jan 5, 2026Jan 7, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
8,475——37,665Jan 5, 2026Jan 7, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,932$27.09$79.4K29,190Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
6,000——0Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
6,000——32,122Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
6,000——6,000Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
6,000——28,892Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,770$33.54$92.9K26,122Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,681$35.54$59.7K22,892Mar 3, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
5,667——11,333Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,000——12,000Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
43,500——43,500Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
5,667——24,573Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,804$32.18$90.2K18,906Jan 6, 2025Jan 7, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
8,476——8,475Jan 3, 2025Jan 7, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
8,476——21,710Jan 3, 2025Jan 7, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
60,000——60,000Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,000——17,000Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,618$21.64$35.0K13,234Jan 24, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
5,448——14,852Jan 20, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
5,448——0Jan 20, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,902$22.32$64.8K9,404Jan 5, 2024Jan 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
8,475——12,306Jan 3, 2024Jan 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
8,475——16,951Jan 3, 2024Jan 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,618$28.36$45.9K3,831Jun 30, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
5,449——5,449Jun 28, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
5,449——5,448Jun 28, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,426——25,426Jan 3, 2023Jan 5, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
135,682——135,682Jan 3, 2023Jan 5, 2023 ↗View →
Other insiders · AGIO
Loading peer insiders…
About this filer
CIK 0001957180
ROLE
Chief Commercial Officer
PRIMARY
AGIO
COMPANIES
1
ACTIVE SINCE
Jan 2023
MARKETPEEL · /INSIDER/0001957180DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback